Profile
ZYBT ZTS TAK HLN TEVA ITCI
Company Name Zhengye Biotechnology Holding Limited Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Intra-Cellular Therapies, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $282.93M $73.16B $47.84B $46.54B $19.08B $14.05B
Employees 0.28K 13.80K 49.28K 24.56K 37.00K 0.86K
CEO Songlin Song Ms. Kristin C. Peck Mr. Christophe Weber Brian James McNamara Richard D. Francis Dr. Sharon Mates Ph.D.
Ratings
ZYBT ZTS TAK HLN TEVA ITCI
Quant Rating Score 3 3 3 2 1
Quant Rating Neutral Neutral Neutral Sell Strong Sell
Trading
ZYBT ZTS TAK HLN TEVA ITCI
Last Close $6.17 $159.19 $15.37 $10.35 $16.64 $131.87
High 52 $14.03 $196.48 $15.46 $11.41 $22.77 $131.91
Low 52 $3.64 $144.45 $12.89 $8.33 $12.82 $68.54
Price vs. 52 Week High -56.02 % -18.98 % -0.58 % -9.29 % -26.92 % -0.03 %
Price vs. 52 Week Low 69.51 % 10.2 % 19.24 % 24.25 % 29.8 % 92.4 %
Total Return
ZYBT ZTS TAK HLN TEVA ITCI
1 Month Return -32.2 % -6.04 % 1.92 % -9.29 % -3.59 % 0 %
3 Month Return 24.14 % -2.64 % 2.6 % 1.87 % 8.83 % 0 %
6 Month Return 0 % -2.52 % 15.91 % 9.41 % -21.66 % 57.51 %
9 Month Return 0 % -17.29 % 7.33 % -1.8 % -4.7 % 81.59 %
YTD Return 0 % -2.3 % 16.09 % 8.49 % -24.5 % 57.89 %
1 Year Return 0 % -8.94 % 17.96 % 24.25 % 0.54 % 92.4 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ZYBT ZTS TAK HLN TEVA ITCI
Dividend Yield Percentage (TTM) - 1.13 % 4.52 % 0.01 % - -
Dividend Paid and Capex Coverage Ration (TTM) 0.94 % 2 % 1.65 % - 2.53 % -227.26 %
Dividend Per Share (TTM) - 1.86 % 196 % 0.05 % - -
Payout Ratio (TTM) 125.42 % 32.25 % 280.28 % - - -
Growth
ZYBT ZTS TAK HLN TEVA ITCI
Asset Growth -3.81 % 8.25 % -9.55 % 87.69 %
Gross Profit Growth -15.41 % 1.76 % 5.47 % 44.88 %
Revenue Growth -18.68 % 5.87 % 4.4 % 46.62 %
Revenue 3 Year - 33.13 % 1.52 % 556.51 %
Revenue 5 Year - 103.83 % -5.5 % 600974.32 %
Revenue 10 Year - 152.69 % -38.45 % 32663.23 %
EBIT Growth -27.82 % -64.98 % -169.63 % 26.77 %
Net Income Growth -32.69 % -54.56 % -193.2 % 46.54 %
Net Income 3 Yeari Growth Per Share - -61.74 % -482.97 % 79.29 %
Net Income 5 Yeari Growth Per Share - 32.36 % -58.26 % 72.95 %
Net Income 10 Yeari Growth Per Share - 35.42 % -140.46 % 32.41 %
Operating Income Growth -31.67 % -56.36 % -169.98 % 26.77 %
Operating Cash Flow Growth (CFG) 177.96 % -26.69 % -8.85 % 41.08 %
Operating 3 Year CFG - -29.25 % 52.26 % 77.79 %
Operating 5 Year CFG - 118.64 % 123.59 % 69.4 %
Operating 10 Year CFG - 384.17 % -81.66 % 10.87 %
EPS Growth - -54.92 % -190 % 50.68 %
EPS Diluted Growth - -54.86 % -190 % 50.68 %
Book Value Per Share - 13.54 % -30.36 % 80.54 %
Share Holder 3 Year Equity Growth Per Share - 40.38 % -49 % 116.52 %
Share Holder 5 Year Equity Growth Per Share - 41.33 % -62.86 % 215.14 %
Share Holder 10 Year Equity Growth Per Share - 195.14 % -82.6 % 164.65 %
Dividend Per Share Growth - 1.95 % - -
Dividend 3 Year Growth Per Share - 1.19 % - -
Dividend 5 Year Growth Per Share - 101.42 % -100 % -
Dividend 10 Year Growth Per Share - 102.58 % -100 % -
Debt Growth 38.49 % 10.53 % -10.29 % 0.25 %
Free Cash Flow Growth 466.1 % -31.4 % -11.05 % 40.95 %
Updated On 31 Dec 2023 31 Mar 2024 31 Dec 2024 31 Dec 2024
Profitability
ZYBT ZTS TAK HLN TEVA ITCI
Gross Profit Margin TTM 61.35 % 70.2 % 54.7 % 61.52 % 49.17 % 91.63 %
Return on Assets TTM 6.29 % 17.86 % 0.76 % 4.2 % -3.35 % -5.46 %
Return on Equity TTM 11.05 % 51.32 % 1.48 % 8.73 % -21.38 % -7.4 %
Return on Capital Employed TTM 12.87 % 32.08 % 3.75 % 7.74 % 1.59 % -10.05 %
Net Income Per EBT TTM 71.88 % 78.79 % 61.12 % 75.5 % 246.36 % 100.64 %
EBT Per Ebit TTM 97.28 % 92.99 % 40.08 % 86.58 % -120.28 % 63.57 %
EBIT Per Revenue TTM 21.25 % 37.01 % 9.62 % 19.64 % 2.61 % -17.15 %
Cash Flow To Debt Ratio TTM 53.63 % 43.63 % 21.32 % - 7.47 % -430.93 %
Receivables Turnover TTM 2.13 6.82 6.32 5.9 4.91 4.09
Payables Turnover TTM 1.79 6.51 4.36 2.19 3.69 2.18
Inventory Turnover TTM 1.4 1.16 1.7 3.63 2.6 2.17
Fixed Asset Turnover TTM 77.96 % 253.65 % 232.78 % 584.75 % 332.7 % 4569.25 %
Asset Turnover TTM 42.34 % 65.87 % 32.15 % 32.73 % 43.25 % 49.79 %
Operating Cash Flow Per Share TTM - 6.58 608.55 - 1.11 -0.71
Free Cash Flow Per Share TTM - 5.1 443.26 - 0.67 -0.71
Cash Per Share TTM - 384.5 % 24349.44 % 24.05 % 149.12 % 970.67 %
Operating Cash Flow Sales Ratio TTM 22.77 % 31.71 % 21.01 % - 7.62 % -10.75 %
Free Cash Flow Operating Cash Flow Ratio TTM 75.93 % 77.45 % 72.84 % - 60.43 % 100.44 %
Cash Flow Coverage Ratios TTM 53.63 % 43.63 % 21.32 % - 7.47 % -430.93 %
Price To Free Cash Flows Ratio TTM 55.38 32.07 9.73 - 25.4 -191.12
Price To Operating Cash Flows Ratio TTM - 24.98 7.13 - 15.23 -185.85
Price Cash Flow Ratio TTM - 24.98 7.13 - 15.23 -185.85
Income Statement (TTM)
ZYBT ZTS TAK HLN TEVA ITCI
Revenue $0.21B $9.26B $4263.76B $11.23B $16.54B $0.68B
Gross Profit $0.13B $6.54B $2832.26B $6.95B $8.06B $0.62B
Gross Profit Ratio 61.35% 70.62% 66.43% 61.85% 48.74% 91.63%
EBITDA $0.07B $3.87B $874.6B $2.51B $0.72B $-0.12B
Net Income $0.03B $2.49B $144.07B $1.44B $-1.64B $-0.07B
EPS Diluted - 5.47 45.58 0.32 -1.45 -0.72
Balance Sheet (MRQ)
ZYBT ZTS TAK HLN TEVA ITCI
Long Term Debt $0.01B $5.39B $5029.93B $8.54B $16.3B $0.01B
Total Liabilities $0.16B $9.47B $7834.79B $18.09B $33.61B $0.22B
Total Equity $0.34B $4.77B $7274.01B $16.22B $5.72B $1.15B
Total Investments $0B $0B $445.7B $0.08B $0B $0.69B
Total Debt $0.09B $6.74B $4843.75B $10.1B $18.08B $0.02B
Total Assets $0.5B $14.24B $15108.79B $34.32B $39.33B $1.37B
Cash Flow Statement (TTM)
ZYBT ZTS TAK HLN TEVA ITCI
Net Income $0.04B $2.5B $144.07B $1.44B $-1.96B $-0.07B
Inventory $-0.01B $-0.04B $-115.74B $0.22B $0.17B $-0.01B
Dividends Paid $-0.04B $-0.79B $-287.19B $-0.57B $0B $0B
Operating Cash Flow $0.05B $2.95B $716.34B $2.3B $1.25B $-0.07B
Capital Expenditure $-0.01B $-0.66B $-480.73B $-0.25B $-0.5B $-0B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.33
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.305
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 9.01
ALVOW Alvotech 1.94
AMPH Amphastar Pharmaceuticals, Inc. 23.4
AMRX Amneal Pharmaceuticals, Inc. 8.265
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 63.3583
APUS Apimeds Pharmaceuticals US, Inc 1.8
AQST Aquestive Therapeutics, Inc. 3.48
ASRT Assertio Holdings, Inc. 0.6515
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 8.8185
ETFs With Exposure to ZYBT
Ticker ETF Name Weight Percentage Price
PGJ Invesco Golden Dragon China ETF 0.201 28.405
Unlock